 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Corixa Corporation
 |
Corixa Corporation |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Corixa reports steeper second-quarter loss Aug 09 2001 01:26 PM PDT
> More WIRE STORIES about this company
NEWS FROM THE STANDARD |
 |
After The Bell: Frantic JDS Trading Continues
Feb 14 2001 04:36 PM PST
PROFILE |
 |
Corixa focuses on T-cell vaccines for treating and preventing cancer and infectious and autoimmune diseases. Flagship product Melacine, a vaccine for late-stage melanoma distributed by Schering-Plough, is approved in Canada and awaiting approval in the US. Lead cancer drug candidate BEXXAR, developed with a unit of GlaxoSmithKline, targets non-Hodgkin's lymphoma. The firm also develops adjuvants, which are added to existing medicines to enhance their efficacy; MPL, for use in allergy vaccines, is in clinical trials. Other candidates target rheumatoid arthritis, multiple sclerosis, and psoriasis, as well as malaria, hepatitis, and other infectious diseases.
COMPETITION |
 |
AVAX Technologies, Inc. (AVXT)
Cell Genesys, Inc. (CEGE)
ImClone Systems Incorporated (IMCL)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 37.00
1-Yr. Sales Growth: 39.6%
Employees: 538
Revenue per employee: $68,773.23
KEY PEOPLE |
 |
Steven Gillis
CEO
Michelle Burris
CFO
CONTACT INFO |
 |
1124 Columbia St., Ste. 200
Seattle, WA 98104
US
Phone: 206-754-5711
Fax: 206-754-5715
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |